Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is conducting a study titled ‘A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels.’ The study aims to evaluate the effectiveness of combining fianlimab with cemiplimab and chemotherapy compared to cemiplimab and chemotherapy alone in treating advanced NSCLC.
The study tests a combination of drugs: fianlimab, cemiplimab, and chemotherapy agents like Pemetrexed and Paclitaxel. Fianlimab and cemiplimab are administered intravenously every three weeks, aiming to enhance treatment efficacy for NSCLC patients.
This interventional study is randomized and follows a parallel assignment model with quadruple masking. Its primary purpose is treatment, focusing on determining the best drug combination for NSCLC patients.
The study began on August 8, 2023, with primary completion expected by July 18, 2025. These dates are crucial for tracking progress and anticipating results that could impact treatment protocols and market dynamics.
The study’s progress could significantly influence Regeneron’s stock performance, as successful outcomes may enhance their market position in oncology. Competitors in the NSCLC treatment space will be closely monitoring these developments.
The study is ongoing, and further details are available on the ClinicalTrials portal.